Is OpenEvidence free? OpenEvidence cost, pricing, and what free access actually buys

Advertising and publisher partnerships. Pharmaceutical and healthcare advertisers pay to reach a verified clinical audience, and the platform licenses content from medical journals for the literature it summarizes. That is a real business model rather than a trial that expires, which is why the free access has held up as the product has grown.

It also explains the verification step, which people sometimes read as gatekeeping for its own sake. The value of the audience to an advertiser is that every member of it is a confirmed prescriber. Verification is not a formality bolted onto the product, it is the thing being sold. Once you see it that way, the eligibility rules stop looking arbitrary: anyone who cannot be verified is, from the funding model's point of view, not part of the product.

None of that makes the tool worse. Plenty of professional software is ad-funded and perfectly good. It does mean a commercial interest sits next to clinical content, and a buyer is entitled to weigh that the same way they would weigh it anywhere else. A subscription you pay for has no such interest, which is part of what the subscription buys.

This is the part that matters if you are deciding for more than yourself, and there is now a concrete example rather than a hypothetical. In 2026 OpenEvidence withdrew from the European Union and the United Kingdom, citing regulatory uncertainty around AI systems including the EU AI Act. The withdrawal covered existing accounts, not just new registrations. Clinicians who had built it into their daily reading lost it, and their credentials made no difference.

That is not a criticism of the decision, which looks like a reasonable response to a genuinely unsettled regulatory position. It is an illustration of where the control sits. When you pay for something you hold a contract, and a vendor that wants to stop serving you has to work through notice periods and renewal terms. When access is a permission the vendor grants, it can be withdrawn on the vendor's timetable, for reasons that have nothing to do with you.

For an individual clinician that risk is small and the price is right. For a practice writing a tool into a standard workflow, or a department training staff around it, it is worth pricing honestly. The question is not whether free is cheaper. It is what happens to your workflow on the day free ends.

OpenEvidence announced on 25 April 2025 that it fully complies with the requirements of HIPAA and that US covered entities can input protected health information in accordance with HIPAA's privacy and security standards, handled under its Business Associate Agreement. That is a clearer public position than most clinical AI tools have taken, and it is worth knowing when the alternative is typing the same question into a general chatbot.

The part that gets misread is who the agreement covers. A BAA protects the covered entity that holds one. An individual clinician using a personal account is not automatically inside their employer's compliance perimeter. Health systems have landed in different places on this: MaineHealth, for one, tells its clinicians in writing not to submit PHI in OpenEvidence queries, noting it has not reached acceptable BAA terms with the vendor and that a clinician's personal agreement does not protect the organization's data.

So the honest answer is that OpenEvidence is HIPAA-capable and your employer may still forbid PHI in it. Those are two separate questions and only one of them is answered by a vendor announcement. Check your own policy first. The same distinction applies to general assistants, which is the ground we cover in OpenEvidence vs ChatGPT.

An evidence engine answers a clinical question. The prescription in front of you raises several safety questions at once: does this interact with what the patient already takes, is it contraindicated, does a documented allergy block it, and does their kidney or liver function change the dose. Asking a literature tool those one at a time is slow, and the check that gets skipped is the one nobody thought to run.

The gap widens as the medication list grows. A polypharmacy review across ten drugs is not a question you can phrase for a literature engine at all, because the answer depends on the specific combination rather than on the published evidence for any one agent. That is a structured, per-patient task, and it is the job a drug interaction checker is built for.

Most clinicians who use both settle into a clean division of labor: the evidence engine for background reading, a decision-support card at the moment of prescribing. Judging either tool on the other's job is how people end up disappointed with both. If renal dosing is where your friction sits, the creatinine clearance calculator covers the arithmetic side of it directly.